Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations

Added 'organic psilocybin substance or' to the list of eligible substances in §60A-2-204(d), clarifying that both organic and crystalline forms of psilocybin are covered under the new prescription laws if federally approved.

Added official dates indicating the bill passed on March 14, 2026, and will take effect 90 days after passage (June 12, 2026).

Added standard legislative signatures for the Senate Clerk, House Clerk, President of the Senate, Speaker of the House, and Governor to certify the bill is enrolled.

Added a footer with website navigation links, contact information, and copyright notices typical of the final published version.

Expanded the list of Schedule I substances in the final version to include numerous synthetic cannabinoids, synthetic cathinones, and specific fentanyl analogs that were not explicitly listed in the draft.

The final version includes a redundant and repetitive listing of controlled substances, repeating categories like synthetic cannabinoids and fentanyl analogs multiple times with slight variations in formatting.